CALGARY, Jan. 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (“Oncolytics”) announced today that the six-month follow up period has been concluded for patients in its Phase I Canadian recurrent malignant glioma clinical trial. As reported in October 2005, intratumoural administration of reovirus was well tolerated by the patients and a maximum tolerated dose was not reached. Surviving patients continue to be monitored and data analysis is ongoing.
“We intend to continue to investigate REOLYSIN(R) as a monotherapy in our U.S. Phase I/II malignant glioma clinical trial, employing an alternative delivery method,” said Dr. Brad Thompson, President and CEO of Oncolytics. “We are also considering the potential use of REOLYSIN(R) in combination with both the chemotherapeutics and radiation therapy that are the current standards of care for malignant glioma.”
The study examined the use of a single, intratumoural injection of REOLYSIN(R), delivered using imaging-guided surgery, in patients with malignant gliomas that had recurred despite other treatments, including surgery and radiation therapy. A total of 12 patients were treated in the study at dosages of 10(7), 10(8), and 10(9) TCID(50) in a delivery volume of 0.9 ml.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN(R), its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics’ researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, bladder, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Previous Phase I clinical trial results have indicated that REOLYSIN(R) was well tolerated and that the reovirus demonstrated activity in tumours injected with REOLYSIN(R).
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company’s expectations related to the results of the Canadian Phase I recurrent malignant glioma clinical trial and the US Phase 1/II trial investigating delivery of REOLYSIN(R) for recurrent malignant gliomas, and the Company’s belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.
Oncolytics Biotech Inc.
CONTACT: Oncolytics Biotech Inc., Brad Thompson, 210, 1167 Kensington CrNW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858,www.oncolyticsbiotech.com; The Equicom Group, Nick Hurst, 20 TorontoStreet, Toronto, Ontario, M5C 2B8, Tel: (416) 815-0700 ext.226, Fax: (416)815-0080, nhurst@equicomgroup.com; The Investor Relations Group, JohnNesbett or Janet Vasquez, 11 Stone St, 3rd Floor, New York, NY, 10004, Tel:(212) 825-3210, Fax: (212) 825-3229, jnesbett@investorrelationsgroup.com;RenMark Financial Communications, John Boidman, 2080 Rene Levesque Blvd.W., Montreal, PQ, H3H 1R6, Tel: (514) 939-3989, Fax: (514) 939-3717,jboidman@renmarkfinancial.com
